Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (DE:8AK)
BERLIN:8AK
Alkermes (8AK) Stock Price & Analysis
0 Followers
8AK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€20.08 - €29.80
Previous Close€22.2
Volume0.00
Average Volume (3M)1.00K
Market Cap
€3.83B
Enterprise Value€3.46B
Total Cash (Recent Filing)$773.49M
Total Debt (Recent Filing)$372.19M
Price to Earnings (P/E)N/A
Beta0.25
Next Earnings
May 01, 2024EPS Estimate
€0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding164,136,728
10 Day Avg. Volume28
30 Day Avg. Volume1,000
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)5.13
Price to Cash Flow (P/CF)28.20
P/FCF Ratio45.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit2.45
Enterprise Value/Ebitda6.66
Forecast
1Y Price Target
€33.15Price Target Upside46.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Alkermes News
PremiumCompany Announcements
Alkermes Reveals Promising Phase 1b Study ResultsBulls Say, Bears Say
Bulls Say
Clinical DevelopmentALKS 2680 has shown a clear dose response in improving wakefulness with a favorable safety profile, positioning it as a strong candidate in the narcolepsy treatment landscape.
Product PerformanceLybalvi is on track to do close to $300M this year, surpassing the $400M peak sales expectation, highlighting the product's strong market acceptance and growth potential.
Strategic PartnershipsHarmony's decision to develop TPM-1116 underscores the importance of the OX2R agonist class, benefiting Alkermes by validating their approach to treating sleep/wake disorders.
Bears Say
Market CompetitionThe orexin program faces stiff competition, which could impact the company's market share and future revenue potential.
Product PerformanceSales for Risperdal Consta are declining, in line with expectations due to increased competition.
Revenue RisksThere's likely to be a meaningful hit to the $410M in annual Vivitrol revenues upon generic entrants in January 2027.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.51% Other Institutional Investors
99.49% Public Companies and
Individual Investors
8AK FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was €20.08 and its highest was €29.80 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is May 01, 2024 which is in 3 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Feb 15, 2024. The company reported €0.205 earnings per share for the quarter, missing the consensus estimate of €0.417 by -€0.212.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is €0.56.
How many shares outstanding does Alkermes have?
Currently, no data Available
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of €0.205 in its last earnings report, missing expectations of €0.417. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 99M.
---
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€33.15 (46.70% Upside)
€33.15 (46.70% Upside)
Blogger Sentiment
Bullish
DE:8AK Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.82%
12-Months-Change
Fundamentals
Return on Equity
35.93%
Trailing 12-Months
Asset Growth
8.77%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
8AK Company Deck
---
8AK Earnings Call
Q4 2024
0:00 / 0:00
---
8AK Stock 12 Months Forecast
Average Price Target
€33.15
▲(46.70% Upside)
Technical Analysis
Alkermes
―
Alnylam Pharma
―
Amgen
―
Arvinas Holding Company
―
BioMarin Pharmaceutical
―
Best Analysts Covering 8AK
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+0.90%
assigned a buy rating 19 days ago
Copying Akash Tewari's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +0.90% per trade.
---